149 results on '"Richardson, Simone I."'
Search Results
2. SARS-CoV-2 humoral immunity in people living with HIV-1
3. Infection pre-Ad26.COV2.S-vaccination primes greater class switching and reduced CXCR5 expression by SARS-CoV-2-specific memory B cells
4. Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages
5. Comparing the immune abnormalities in MIS-C to healthy children and those with inflammatory disease reveals distinct inflammatory cytokine production and a monofunctional T cell response
6. Functional consequences of allotypic polymorphisms in human immunoglobulin G subclasses
7. Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b–2a trial
8. Hemagglutinin stalk-specific Fc-mediated functions are associated with protection against influenza-illness after seasonal influenza vaccination in pregnant women
9. Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants
10. Antibody class-switching as a strategy to improve HIV-1 neutralization
11. Enhanced neutralization potency of an identical HIV neutralizing antibody expressed as different isotypes is achieved through genetically distinct mechanisms
12. Emergence and phenotypic characterization of the global SARS-CoV-2 C.1.2 lineage
13. Development of LIBRA-seq for the guinea pig model system as a tool for the evaluation of antibody responses to multivalent HIV-1 vaccines
14. Comparing the immune abnormalities in MIS-C to healthy children and those with inflammatory disease reveals distinct inflammatory cytokine production and a monofunctional T cell response
15. Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants
16. Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection
17. Development of LIBRA-seq for the Guinea Pig Model System as a Tool for the Evaluation of Antibody Responses to Multivalent HIV-1 Vaccines
18. Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination
19. The antibody response in HIV-1-infected donors
20. Functional HIV-1/HCV cross-reactive antibodies isolated from a chronically co-infected donor
21. Antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron sub-lineages is reduced in convalescent sera regardless of infecting variant
22. Common helical V1V2 conformations of HIV-1 Envelope expose the α4β7 binding site on intact virions
23. Novavax NVX-COV2373 triggers potent neutralization of Omicron sub-lineages
24. Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b–2a trial
25. Enhanced neutralization potency of an identical HIV neutralizing antibody expressed as different isotypes is achieved through genetically distinct mechanisms
26. Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants
27. Functional consequences of allotypic polymorphisms in human immunoglobulin G subclasses
28. SARS-CoV-2 BA.4 infection triggers more cross-reactive neutralizing antibodies than BA.1
29. SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals
30. HIV Prevention in a Time of COVID-19: A Report from the HIVR4P // Virtual Conference 2021
31. Influenza Vaccination Results in Differential Hemagglutinin Stalk-Specific Fc-Mediated Functions in Individuals Living With or Without HIV
32. Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern
33. SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity
34. SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated individuals
35. Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern
36. A SARS-CoV-2 variant of concern triggers Fc effector function with increased cross-reactivity
37. Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner
38. Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions
39. HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function
40. Targeting Fc effector function in vaccine design
41. Cross-reactive coronavirus antibodies with diverse epitope specificities and extra-neutralization functions
42. Antibody Isotype Switching as a Mechanism to Counter HIV Neutralization Escape
43. Hinge length contributes to the phagocytic activity of HIV-specific IgG1 and IgG3 antibodies
44. IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibody
45. V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity
46. Measuring the ability of HIV-specific antibodies to mediate trogocytosis
47. HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies
48. South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on α4β7 for replication
49. The Sequence of the α4β7-binding Motif on Gp120 of Transmitted/Founder Viruses Contributes to the Dependence on the Integrin for HIV Infection
50. Antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron sub-lineages is reduced in convalescent sera, regardless of the infecting variant
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.